Cargando…
O028 Combination Pharmacological Therapy Targeting Multiple Mechanisms of Sleep Apnea
INTRODUCTION: Currently two leading experimental pharmacological interventions are under investigation for obstructive sleep apnea (OSA). Acetazolamide, which acts to stabilise ventilatory control, lowers the apnea-hypopnea index (AHI) by ∼38%. More recently, atomoxetine-plus-oxybutynin (“AtoOxy”),...
Autores principales: | Sands, S, Hess, L, Bertisch, S, Collet, J, Gell, L, Calianese, N, Vena, D, Azarbarzin, A, Taranto-Montemurro, L, Wellman, A, Landry, S, Thomson, L, Joosten, S, Hamilton, G, Edwards, B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109095/ http://dx.doi.org/10.1093/sleepadvances/zpac029.027 |
Ejemplares similares
-
O027 The combination of mandibular advancement devices (MAD) and supplemental oxygen dramatically improves OSA severity: preliminary results from the MADOX trial
por: Edwards, B, et al.
Publicado: (2021) -
Reply to Patel and Althouse: Robust Methods Are Needed to Evaluate the Pharmacologic Treatment of Obstructive Sleep Apnea
por: Taranto-Montemurro, Luigi, et al.
Publicado: (2019) -
O055 Flow limitation and sleepiness in individuals without sleep apnea
por: Mann, D, et al.
Publicado: (2022) -
O057 The Impact of Surgical Weight Loss on the Physiological Endotypes causing Obstructive Sleep Apnea
por: Beatty, C, et al.
Publicado: (2023) -
Targeting Endotypic Traits with Medications for the Pharmacological Treatment of Obstructive Sleep Apnea. A Review of the Current Literature
por: Taranto-Montemurro, Luigi, et al.
Publicado: (2019)